At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cannabinoid Control of Fear Extinction Neural Circuits in Humans
In Brief
A Phase 4 clinical trial evaluating Dronabinol and Placebo for Healthy Participants. Completed, enrolled 85 participants.
Detailed Summary
The goal of the current proposal is to investigate the effects of a cannabinoid drug on the memory of extinguished fear in humans and the brain circuitry important for the recall of extinction learning. The investigators findings will translate previous discoveries from animal studies to humans and increase their understanding of the neurobiological mechanisms supporting retention of extinction memory. This proof-of-concept study is a critical translational first step towards the development of cannabinoid modulators as an adjunctive strategy to exposure-based therapies to augment extinction learning and prevent the return of fear memories in patients with post-traumatic stress and other anxiety disorders.
Study Details
Timeline
Interventions
Dronabinol (7.5mg) is administered only once by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants will receive dronabinol.
Placebo is administered only once by the oral route and contains only dextrose in opaque capsules. Half of the participants will receive placebo.